Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel … Read more
Energenesis Biomedical Co. Ltd. (6657) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.036x
Based on the latest financial reports, Energenesis Biomedical Co. Ltd. (6657) has a cash flow conversion efficiency ratio of -0.036x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-35.38 Million) by net assets (NT$993.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Energenesis Biomedical Co. Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Energenesis Biomedical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Energenesis Biomedical Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Energenesis Biomedical Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Integrated Wind Solutions AS
OL:IWS
|
0.104x |
|
Shanthi Gears Limited
NSE:SHANTIGEAR
|
0.118x |
|
New Power Plasma Co.Ltd
KQ:144960
|
0.051x |
|
PT Harum Energy Tbk
F:44H
|
0.010x |
|
SCHMID Group N.V. Class A Ordinary Shares
NASDAQ:SHMD
|
0.000x |
|
LuxExperience B.V.
NYSE:LUXE
|
-0.116x |
|
Kee Tai Properties Co Ltd
TW:2538
|
-0.036x |
|
Uniplus Electronics Co Ltd
TWO:5381
|
0.010x |
Annual Cash Flow Conversion Efficiency for Energenesis Biomedical Co. Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Energenesis Biomedical Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$739.33 Million | NT$-180.71 Million | -0.244x | +12.68% |
| 2023-12-31 | NT$803.98 Million | NT$-225.05 Million | -0.280x | +27.56% |
| 2022-12-31 | NT$602.56 Million | NT$-232.84 Million | -0.386x | -238.56% |
| 2021-12-31 | NT$852.38 Million | NT$-97.29 Million | -0.114x | +22.36% |
| 2020-12-31 | NT$672.92 Million | NT$-98.92 Million | -0.147x | +4.61% |
| 2019-12-31 | NT$786.49 Million | NT$-121.20 Million | -0.154x | -- |